The influence of nonsteroidal anti-inflammatory drugs on deaminase adenosine activity;Wpływ niesteroidowych leków przeciwzapalnych na aktywność deaminazy adenozyny

Polskie Archiwum Medycyny Wewnetrznej

Volumn 116, Issue 3, 2006, Pages 832-837

  Kopff, Anna ^a   Kopff, Maria ^b   Kowalczyk, Edward ^c  

^a II Klinika Kardiologii UM W odzi

^b Katedra Chemii I Biochemii Klinicznej UM W odzi

^c Zakład Fizjologii Człowieka I Biofizyki UM W Łodzi ^*

Author keywords

Deaminase adenosine activity; Nonsteroidal anti inflammatory drugs

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DEAMINASE; DICLOFENAC; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL EXPERIMENT; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; NONHUMAN; RAT;

ADENOSINE DEAMINASE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; DICLOFENAC; ERYTHROCYTES; FEMALE; ISOENZYMES; MALE; RATS; RATS, WISTAR; SULFONAMIDES;

EID: 33846781313     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Williams C.S., Du Bois R.N.: Prostaglandin endoperoxide synthase: why two isoforms? Am. J. Physiol., 1996, 270, G393.
2. Xie W.L., Chipman J.G., Robertson D.L., Erikson R.L., Simmons D.L.: Expression a mitogen-responsive gene encoding prostaglsndin synthase is a regulated by mRNA splicing. Proc. Natl. Acad. Sci. USA., 1991, 88, 2692.
3. Smith W.L.: Prostanoid bio-sythesis and mrchanism of action. Am. J. Physiol., 1992, 263, F118.
4. Chandrasekharan N.V., Dai H., Roos L.T. i wsp.: COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure and expression. Proc. Natl. Acad. Sci. USA., 2002, 99, 13926.
5. Fox J.H., Kelly W.N.: The role of adenosine and 2′ deoxyadenosine in mammalian cells. Ann Rev Biochem., 1978, 47, 655.
6. Schrader W.P., Stacy A.R.: Purification of adenosine deaminase complexing protein from human plasma. J. Biol. Chem., 1979, 254, 11964.
7. Ungerer J.P.J., Oosthuizen H.M., Bissbort S.H., Vermaak W.J.H.: Serum adenosine deaminase: isoenzymes and diagnostic application. Clin. Chem., 1992, 38, 1333.
8. Ratech H., Hirschhorn R.: Serum adenosine deaminase in normals and in a patient with adenosine deaminase deficiency - severe combined immunodeficiency. Clin. Chim. Acta., 1981, 115, 341.
9. Ratech H., Thorbecke G.J., Meredith G., Hirschhorn R.: Comparison and possible homology of isoenzymes of adenosine deaminase in aves and humans. Enzyme., 1981, 26, 74.
10. rd ed. Verlag Chemie, Weinheim, 315.
11. 2: diagnostic and bilogical role. Eur. Respir. J., 1996, 9, 632.
12. Hopkinson D.A., Cook P.J.L., Harris H.: Further data on the adenosine deaminase polymorphism and report of new phenotype. Ann. Hum. Genet., 1969, 32, 361.
13. Muraoka T., Katsuramaki T., Shiraishi H., Yokoyama M.M.: Automated enzymatic measurement of adenosine deaminase isoenzyme activities in serum. Anal. Biochem., 1990, 187, 268.
14. Newby A.C., Worku Y., Meghji P. Critical evaluation of role of ecto-and cytosolic 5′-nucleotidase in adenosine formation. [w:] Topics and Perspectives in Adenosine Research. (red.) Gerlach E., Becker B.F.; Berlin, Heidelberg, Springer-Verlag., 1987, 155.
15. Hori M., Kitakaze M.: Adenosine, the heart and coronary circulation. Hypertension., 1991, 18, 565.
16. Pearson J.D.: Adenosine uptake and adenine nucleotide metabolism by vascular endothelium. [w:] Regulatory Function of Adenosine. (red.) Berne R.M., Rall T.W., Rubio R., Hague, Martinus-Nijhoff., 1983, 252.
17. Ohisallo J.J.: Regulation function of adenosine. Med. Biol., 1987, 65, 187.
18. Nees S., Des Rosiers C., Bock M.: Adenosine receptors at the coronary endothelium. Functional implications. [w:] Topics and Perspectives in Adenosine Research. (red.) Gerlach E., Becker B.F. Berlin, Springer-Verlag., 1987, 454.
19. Olanrewaju H.A., Hargittai P.T., Lieberman E.A., Mustafa S.J.: Role of endothelium in hyperpolarization of coronary smooth muscle by adenosine and its analogues. J. Cardiovasc. Pharmacol., 1995, 25, 234.
20. Kitakaze M., Hori M., Sato H. i wsp.: Endogenous adenosine inhibits platelet aggregation during myocardial ischemic in dogs. Circ. Res., 1991, 69, 1402.
21. Cronstein B.N., Levin R.I., Belanoff J., Weissman G., Hirschhorn R.: Adenosine: an endogenous inhibitor of neutrophil mediated injury to endothelial cells. J. Clin. Invest., 1986, 78, 760.
22. -. generation respectively. J. Clin. Invest., 1990, 85, 1150.
23. Funaya H., Kitakaze M., Node K., Minamoto T., Komamura K., Hori M.: Plasma adenosine levels increase in patients with chronixc heart failure. Circulation., 1997, 95, 1365.
24. Tracey W.R., Magee W., Masamune H. i wsp.: Selective adenosine A3 receptor stimulation reduces ischemic myocardial injury in the rabbit heart. Cardiovasc. Res., 1997, 33, 410.
25. 2 receptors adenosine inhibits the production of tumor necrosis factor-α of endotoxin-stimulated human polymorphonucleear leukocytes. J. Lab. Clin. Med., 1995, 126, 275.
26. Minamoto T., Kitakaze M., Node K. i wsp.: Adenosine inhibits leukocyte-induced vasoconstriction. Am. J. Physiol., 1996, 271, 2623.
27. Van der Weyden M.B., Kelley W.N.: Human adenosine deaminase: distribution and properties. J. Biol. Chem., 1976, 251, 5448.
28. Giblett E.R., Anderson J.E., Cohen F., Pollara B., Meuwissen H.J.: Adenosine deficience in two patients with severely impaired cellular immunity. Lancet., 1972, 2, 1067.
29. Cronstein B.N., Montesinois M.C., Weissmann G.: Salicylates and sulfasalazine, but not glucocorticoids, inhibit leukocyte accumulation by an adenosine-dependent mechanism that is independent of inhibition of prostaglandin synthesis and p105 of NFkappaB. Proc. Natl. Acad. Sci. USA., 1999, 96, 6377.
30. Cronstein B.N., Montesinos M.C., Weissmann G.: Sites of action for future therapy: an adenosine-dependent mechanism by which aspiryn retains its antiinflamatory activity in cyclooxygenase-2 and Nfkappa knockout mice. Osteoarthritis Cartilage., 1999, 7, 361.